Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryxta
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bryxta is a biosimilar of bevacizumab, a recombinant humanized monoclonal antibody that acts as an antineoplastic agent. It specifically targets and binds to the vascular endothelial growth factor (VEGF), preventing its interaction with receptors VEGFR-1 and VEGFR-2 on the surface of endothelial cells. By neutralizing VEGF, Bryxta inhibits angiogenesis—the formation of new blood vessels—thereby depriving tumors of the blood supply, oxygen, and nutrients required for growth and metastasis. Developed by Zydus Lifesciences, it is indicated for the treatment of various malignancies, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and certain gynecological cancers such as ovarian and cervical cancer. It is administered via intravenous infusion.
- Brand names
- Bryxta
- Other names
- bevacizumab biosimilar
02
Targets
Beyond the preview
Go deeper on Bryxta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bryxta.